Neuronix announced positive results from its pivotal, double-blind placebo-controlled, multi-center clinical study, for the assessment of safety and efficacy of the neuroAD Therapy System, in the treatment of mild to moderate Alzheimer's disease. Neuronix has filed a U.S. FDA application seeking regulatory clearance to market its neuroAD Therapy System for treatment of Alzheimer's disease. If approved, the neuroAD Therapy System would be the first medical device ever cleared by the FDA for treatment of Alzheimer's. neuroAD is a patent-protected, non-invasive medical device, uniquely combining transcranial magnetic stimulation (TMS) with cognitive training, to concurrently target brain regions affected.